Psychiatry needs new innovative treatment approaches as the classical approaches don’t offer sufficient results. Depression is well recognized by the WHO as the 1st cause of disability worldwide. The pandemic has increased the number of patients suffering from depression and some estimates are that more than 300 million people in the world are suffering from depression. Around one-third of these patients are classified as Treatment-Resistant patients to medications and do not benefit sufficiently from antidepressants. Therefore alternative treatments should be offered to patients. rTMS and Ketamine Treatments are offered nowadays but are not readily available to patients in many areas. Other psychedelic substances and non-pharmacological treatments are currently being investigated.
This Research Topic aims to enhance the information available to clinicians and researchers investigating these approaches to shed more light on different treatment options in treatment-resistant depression. The end goal is to empower and help patients to seek help accordingly for their depression.
We welcome the following article types: Original Research articles; Reviews; Mini-reviews; Perspectives; Opinions; Case Reports; and Brief Research Reports and encourage submissions on but not limited to the following topics:
• Ketamine Treatment in Psychiatry
• rTMS Treatment in Neuropsychiatry
• Psychedelic Treatments in Psychiatry
• Alternative pharmacological treatments in Psychiatry
• Treatment-Resistant Depression
• 21 Century treatments in Psychiatry
• MDMA, LSD, Psilocybin in Psychiatry
Psychiatry needs new innovative treatment approaches as the classical approaches don’t offer sufficient results. Depression is well recognized by the WHO as the 1st cause of disability worldwide. The pandemic has increased the number of patients suffering from depression and some estimates are that more than 300 million people in the world are suffering from depression. Around one-third of these patients are classified as Treatment-Resistant patients to medications and do not benefit sufficiently from antidepressants. Therefore alternative treatments should be offered to patients. rTMS and Ketamine Treatments are offered nowadays but are not readily available to patients in many areas. Other psychedelic substances and non-pharmacological treatments are currently being investigated.
This Research Topic aims to enhance the information available to clinicians and researchers investigating these approaches to shed more light on different treatment options in treatment-resistant depression. The end goal is to empower and help patients to seek help accordingly for their depression.
We welcome the following article types: Original Research articles; Reviews; Mini-reviews; Perspectives; Opinions; Case Reports; and Brief Research Reports and encourage submissions on but not limited to the following topics:
• Ketamine Treatment in Psychiatry
• rTMS Treatment in Neuropsychiatry
• Psychedelic Treatments in Psychiatry
• Alternative pharmacological treatments in Psychiatry
• Treatment-Resistant Depression
• 21 Century treatments in Psychiatry
• MDMA, LSD, Psilocybin in Psychiatry